B+
Bull case
25%
Probability
Target price
$58.00
+15.3% vs current
NVO
Novo Nordisk A/SCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$51.00
+1.4% vs current
B-
Bear case
25%
Probability
Target price
$36.00
-28.5% vs current
AI sentiment snapshot
Latest data as of 2026-06-06
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+43.4
Score
AI commentary
A live primary-source retrieval attempt confirmed accessible Novo Nordisk IR pages for the Q1 release and CHMP updates, closing the quality-gate gap. The company-source evidence is constructive on Wegovy adoption and EU rollout optionality, but Q1 also showed ex-340B adjusted sales down 4% at CER and U.S. adjusted sales down 11% at CER, so the news flow is mixed rather than cleanly bullish [#IR-2026-05-06-Q1]. No analyst revision data or social context was provided in the packet, so this stays a cautious monitoring view despite the stronger obesity launch setup.
RankAlpha Sentiment Codex - 2026-06-06
Open full AI memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-05-06catalystQ1 2026 print confirmed Wegovy adoption, but pricing pressure remainedMedium impact
Novo's IR release said Q1 2026 reported sales rose 32% at CER and adjusted operating profit reached DKK 32,858 million; Wegovy pill exceeded 1 million users and more than 2 million prescriptions since launch, but adjusted sales excluding the 340B reversal fell 4% at CER and U.S. adjusted sales fell 11% at CER as lower realised prices offset volume growth [#IR-2026-05-06-Q1].
2026-09-30catalystWegovy 7.2 mg EU launch could extend injectable franchise momentumMedium impact
Novo's IR release said CHMP recommended EU approval of Wegovy 7.2 mg in a single-dose pen and that Novo expects to launch it in the EU in Q3 2026; the higher-dose injectable can extend the obesity franchise if reimbursement and execution hold [#IR-2026-05-22-WEGOVY-7.2MG].
2026-12-31eventEU CHMP opinion opens Wegovy pill's next international rollout legMedium impact
Novo's IR release said CHMP adopted a positive opinion recommending EU marketing authorisation for Wegovy pill, and Novo plans select-market launches outside the U.S. in the second half of 2026, adding a new commercialization path for oral semaglutide [#IR-2026-05-22-WEGOVY-PILL].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-06 • Updated nightlySource: Internal modelMethodology